Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients

Next Previous
Trial Profile

Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs IM 23 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Beijing Immunochina Medical Science and Technology

    • Most Recent Events

    • 20 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top